OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 126 filers reported holding OCULAR THERAPEUTIX INC in Q1 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $189,543 | -85.7% | 60,364 | -76.5% | 0.00% | – |
| Q2 2023 | $1,327,503 | +115.2% | 257,268 | +119.8% | 0.00% | – |
| Q1 2023 | $616,832 | +694.7% | 117,046 | +323.7% | 0.00% | – |
| Q4 2022 | $77,620 | -17.4% | 27,623 | +21.9% | 0.00% | – |
| Q3 2022 | $94,000 | -50.3% | 22,658 | -51.7% | 0.00% | – |
| Q2 2022 | $189,000 | -59.4% | 46,944 | -29.5% | 0.00% | – |
| Q4 2021 | $465,000 | -68.3% | 66,575 | -54.6% | 0.00% | – |
| Q3 2021 | $1,465,000 | -35.2% | 146,557 | -8.1% | 0.00% | – |
| Q2 2021 | $2,260,000 | +233.8% | 159,395 | +286.4% | 0.00% | – |
| Q1 2021 | $677,000 | -37.9% | 41,246 | -21.7% | 0.00% | – |
| Q4 2020 | $1,090,000 | +376.0% | 52,653 | +74.8% | 0.00% | – |
| Q3 2020 | $229,000 | -79.3% | 30,126 | -77.3% | 0.00% | -100.0% |
| Q2 2020 | $1,107,000 | +412.5% | 132,900 | +205.0% | 0.00% | – |
| Q1 2020 | $216,000 | +137.4% | 43,579 | +223.1% | 0.00% | – |
| Q2 2018 | $91,000 | – | 13,489 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
| Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
| Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
| NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
| Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
| Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
| Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
| BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |